Treatment of chronic kidney disease-associated pruritus: status quo and future prospect

YANG Xing; LUO Yankun

doi:10.7619/jcmp.20223379

Journal of Clinical Medicine in Practice > 2023 > 27(6): 141-144, 148. > DOI: 10.7619/jcmp.20223379

YANG Xing, LUO Yankun. Treatment of chronic kidney disease-associated pruritus: status quo and future prospect[J]. Journal of Clinical Medicine in Practice, 2023, 27(6): 141-144, 148. DOI: 10.7619/jcmp.20223379

Citation:

PDF (681 KB)

Treatment of chronic kidney disease-associated pruritus: status quo and future prospect

YANG Xing¹,
LUO Yankun^2, ,

1.
the Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, 030012
2.
Nephrology Department, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, 030012

More Information

Received Date: November 11, 2022
Revised Date: January 06, 2023
Available Online: April 11, 2023

Graphical Abstract

Abstract

Abstract

Chronic kidney disease-associated pruritus is a common complication in hemodialysis patients, with a high incidence and serious impact on the quality of life of patients, and patients may have depressive states, decreased sleep quality, and increased mortality. Because the pathogenesis of this complication is unknown, there is no clear treatment. Current clinical and related studies can provide a variety of remission methods, including improving the quality of dialysis and systemic drug therapy (calcium channel modulators, opioids, sodium thiosulfate, antihistamines, antidepressants), topical drug therapy, acupuncture or acupressure, treatments of traditional Chinese medicine, etc. This article reviewed the treatment status and progress of this complication in order to provide reference for clinicians to make treatment plans.
- chronic kidney disease-associated pruritus,
- uremic pruritus,
- hemodialysis,
- gabapentin,
- pregabalin,
- opioids,
- sodium thiosulfate

FullText(HTML)

References (42)

References

[1]	RAYNER H C, LARKINA M, WANG M A, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis[J]. Clin J Am Soc Nephrol, 2017, 12(12): 2000-2007. doi: 10.2215/CJN.03280317
[2]	OFENLOCH R, GROCHULSKA K, METTANG T, et al. The incidence of chronic itch in patients on haemodialysis and associated factors[J]. Br J Dermatol, 2022, 186(6): 1052-1054. doi: 10.1111/bjd.21024
[3]	SUKUL N, SPEYER E, TU C, et al. Pruritus and patient reported outcomes in non-dialysis CKD[J]. Clin J Am Soc Nephrol, 2019, 14(5): 673-681. doi: 10.2215/CJN.09600818
[4]	TRACHTENBERG A J, COLLISTER D, RIGATTO C. Recent advances in the treatment of uremic pruritus[J]. Curr Opin Nephrol Hypertens, 2020, 29(5): 465-470. doi: 10.1097/MNH.0000000000000625
[5]	王颖, 毕慧欣. 维持性血液透析患者皮肤瘙痒相关机制的研究进展[J]. 中国血液净化, 2021, 20(1): 43-46. doi: 10.3969/j.issn.1671-4091.2021.01.10
[6]	宛家奎, 水润芝, 李金玉, 等. 高通量血液透析和低通量血液透析治疗尿毒症的效果比较[J]. 医学综述, 2022, 28(5): 1036-1040. doi: 10.3969/j.issn.1006-2084.2022.05.036
[7]	刘红, 回雪玲, 刘书馨. 不同通量透析对尿毒症患者5年远期预后的影响[J]. 中国慢性病预防与控制, 2022, 30(4): 286-289. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXB202204011.htm
[8]	付志辉, 陈莉, 赵子强. 血液灌流联合血液透析治疗尿毒症皮肤瘙痒的临床疗效[J]. 上海医药, 2020, 41(1): 19-20, 55. https://www.cnki.com.cn/Article/CJFDTOTAL-SYIY202001008.htm
[9]	蒙军平, 李占亭, 张涵, 等. 不同透析方式对维持性血液透析患者的影响[J]. 实用临床医药杂志, 2020, 24(15): 38-41. doi: 10.7619/jcmp.202015011
[10]	YOSIPOVITCH G, ROSEN J D, HASHIMOTO T. Itch: From mechanism to (novel) therapeutic approaches[J]. J Allergy Clin Immunol, 2018, 142(5): 1375-1390. doi: 10.1016/j.jaci.2018.09.005
[11]	HERCZ D, JIANG H S, WEBSTER C A. Interventions for itch in people with advanced chronic kidney disease[J]. Cochrane Database Syst Rev, 2020, 12: CD011393.
[12]	王玉梅. 普瑞巴林胶囊联合甲钴胺注射剂治疗尿毒症透析致皮肤瘙痒的临床研究[J]. 中国临床药理学杂志, 2018, 34(3): 237-239. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201803014.htm
[13]	ALTHOBAITI Y S, ALMUTAIRI F M, ALSHEHRI F S, et al. Involvement of the dopaminergic system in the reward-related behavior of pregabalin[J]. Sci Rep, 2021, 11(1): 10577. doi: 10.1038/s41598-021-88429-8
[14]	KUMAGAI H, EBATA T, TAKAMORI K, et al. Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients[J]. Am J Nephrol, 2012, 36(2): 175-183. doi: 10.1159/000341268
[15]	KUMAGAI H, EBATA T, TAKAMORI K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase Ⅲ, randomized, double-blind, placebo-controlled study[J]. Nephrol Dial Transplant, 2010, 25(4): 1251-1257. doi: 10.1093/ndt/gfp588
[16]	WIECZOREK A, KRAJEWSKI P, KOZIOŁ-GAŁCZYNSKA M, et al. Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus[J]. J Eur Acad Dermatol Venereol, 2020, 34(10): 2368-2372. doi: 10.1111/jdv.16360
[17]	COWAN A, KEHNER G B, INAN S. Targeting itch with ligands selective for κ opioid receptors[J]. Handb Exp Pharmacol, 2015, 226: 291-314.
[18]	FISHBANE S, JAMAL A, MUNERA C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus[J]. N Engl J Med, 2020, 382(3): 222-232. doi: 10.1056/NEJMoa1912770
[19]	MATHUR V S, KUMAR J, CRAWFORD P W, et al. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus[J]. Am J Nephrol, 2017, 46(6): 450-458. doi: 10.1159/000484573
[20]	DARRIEURTORT-LAFFITE C, BERTRAND-VASSEUR A, GARRAUD T, et al. Tolerance and effect of sodium thiosulfate in calcific tendinitis of the rotator cuff[J]. Clin Rheumatol, 2020, 39(2): 561-569. doi: 10.1007/s10067-019-04793-x
[21]	FARES I, BOUATTAR T, KONE H M, et al. Calciphylaxis: successful management of a rare complication of chronic kidney disease in two patients[J]. Case Rep Nephrol, 2019, 2019: 1630613.
[22]	RAGGI P, BOULAY A, CHASAN-TABER S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease[J]. J Am Coll Cardiol, 2002, 39(4): 695-701. doi: 10.1016/S0735-1097(01)01781-8
[23]	HUNT G M, RYDER H F. Metabolic acidosis after sodium thiosulfate infusion and the role of hydrogen sulfide[J]. Clin Case Rep, 2018, 6(8): 1595-1599.
[24]	LU P H, CHUO H E, KUO K L, et al. Clinical efficacy and safety of sodium thiosulfate in the treatment of uremic pruritus: a meta-analysis of randomized controlled trials[J]. Toxins, 2021, 13(11): 769.
[25]	SONG Y H, WANG S Y, LANG J H, et al. Therapeutic effect of intravenous sodium thiosulfate for uremic pruritus in hemodialysis patients[J]. Ren Fail, 2020, 42(1): 987-993.
[26]	唐琦, 张黎明, 胡小华, 等. 硫代硫酸钠联合血液灌流对维持性血液透析患者顽固性皮肤瘙痒及氧化应激的影响[J]. 中国血液净化, 2022, 21(1): 33-37, 47. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJH202201010.htm
[27]	刘勇, 童昌军. 加巴喷丁与酮替芬在治疗尿毒症瘙痒中的对比[J]. 锦州医科大学学报, 2018, 39(6): 32-35. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYX201806009.htm
[28]	MOHAMMADI KEBAR S, SHARGHI A, GHORGHANI M, et al. Comparison of gabapentin and hydroxyzine in the treatment of pruritus in patients on dialysis[J]. Clin Exp Dermatol, 2020, 45(7): 866-871.
[29]	GOBO-OLIVEIRA M, PIGARI V G, OGATA M S, et al. Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial[J]. Eur J Dermatol, 2018, 28(4): 488-495.
[30]	WANG X D, YANG G, BAI Y, et al. The behavioral study on the interactive aggravation between pruritus and depression[J]. Brain Behav, 2018, 8(6): e00964.
[31]	WEISSHAAR E, SZEPIETOWSKI J C, DALGARD F J, et al. European S2k guideline on chronic pruritus[J]. Acta Derm Venereol, 2019, 99(5): 469-506.
[32]	KUBANEK A, PAUL P, PRZYBYLAK M, et al. Use of sertraline in hemodialysis patients[J]. Medicina: Kaunas, 2021, 57(9): 949.
[33]	GHOLYAF M, SHEIKH V, YASREBIFAR F, et al. Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study[J]. Int Urol Nephrol, 2020, 52(6): 1155-1165.
[34]	YOSHIDA Y, HIRAMA A, HASHIMOTO K, et al. Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: a multicenter, open-label, randomized verification study[J]. J Dermatol, 2021, 48(9): 1327-1335.
[35]	SOLAK B, ACIKGOZ S B, SIPAHI S, et al. Epidemiology and determinants of pruritus in pre-dialysis chronic kidney disease patients[J]. Int Urol Nephrol, 2016, 48(4): 585-591.
[36]	MOLDOVAN D, RACASAN S, KACSO I M, et al. Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism[J]. Int Urol Nephrol, 2015, 47(11): 1871-1877.
[37]	陈娟娟, 刘素贞, 杨义芳, 等. 血液灌流联合高通量血液透析对尿毒症性皮肤瘙痒的疗效及其对患者钙磷代谢和肾功能的影响[J]. 中国医学前沿杂志: 电子版, 2021, 13(2): 89-92. https://www.cnki.com.cn/Article/CJFDTOTAL-YXQY202102017.htm
[38]	XIONG W, HE F F, YOU R Y, et al. Acupuncture application in chronic kidney disease and its potential mechanisms[J]. Am J Chin Med, 2018, 46(6): 1169-1185.
[39]	KILIÇ AKÇA N, TAŞCI S. Acupressure and transcutaneous electrical acupoint stimulation for improving uremic pruritus: a randomized, controlled trial[J]. Altern Ther Health Med, 2016, 22(3): 18-24.
[40]	YAN C N, YAO W G, BAO Y J, et al. Effect of auricular acupressure on uremic pruritus in patients receiving hemodialysis treatment: a randomized controlled trial[J]. Evid Based Complement Alternat Med, 2015, 2015: 593196.
[41]	张矿军, 张盼盼, 孙丹丹. 尿毒症患者的中药结肠透析联合血液透析研究[J]. 实用临床医药杂志, 2020, 24(22): 44-46. doi: 10.7619/jcmp.202022012
[42]	葛俭俭. 尿毒症性皮肤瘙痒症诊治的系统论述[D]. 重庆: 重庆医科大学, 2019.

Cited By

Cited by

Periodical cited type(9)

1.	邵文嘉，崔金全. 子宫动脉血流参数、血清IL-6、IFN-γ水平与复发性流产患者妊娠结局的相关性. 河南医学研究. 2024(04): 675-679 .
2.	宋红艳，崔天薇，石少琦，肖惠冬子，卫爱武. 丹寿汤对不明原因复发性流产白介素-16表达水平及蜕膜化调控的意义. 时珍国医国药. 2024(01): 129-132 .
3.	管珊，邵姗姗，陈洪. 血清SAA、IFN-γ及子宫动脉血流参数评估不明原因复发性流产效果. 中国计划生育学杂志. 2024(04): 769-773 .
4.	邢景娜，薛娟，闫娜，任红伟. 桂枝茯苓胶囊联合补中益气丸治疗气虚血瘀型药物流产不全的效果研究. 中国计划生育和妇产科. 2024(10): 46-50 .
5.	李欢，张坤. 原因不明复发性流产患者血清sFlt-1、E-cadherin、IFN-γ水平变化及其临床意义. 湖南师范大学学报(医学版). 2024(04): 65-68 .
6.	吴莎莎，邹智勇，陈霞. 早期自然流产合并HCMV感染患者血清IFN-γ、sIL-2R、SAA水平变化及意义. 热带医学杂志. 2024(12): 1738-1741 .
7.	潘惠娟，张春芳，杨凤娜，魏志玲，王芳. 不明原因复发性流产再次妊娠早孕期患者MCV、HCG、IFN-γ/IL-10比值与妊娠结局的关系研究. 现代生物医学进展. 2023(05): 898-903 .
8.	赵朵朵，王丽. 依诺肝素钠联合羟氯喹治疗复发性流产的效果观察. 淮海医药. 2023(05): 516-519 .
9.	王甜甜. 黄体酮结合固肾保胎汤治疗先兆流产临床观察. 实用中医药杂志. 2023(12): 2438-2440 .

Other cited types(1)

Get Citation

PDF

XML

Article views (297) PDF downloads (84) Cited by(10)

Turn off MathJax

Article Contents

Abstract

References

Treatment of chronic kidney disease-associated pruritus: status quo and future prospect

Abstract

References

Cited by

Periodical cited type(9)

Other cited types(1)

Catalog

Export File

Citation

Format

Content